protein

Human Apo B-100

MBS318093

1 mg

255 USD

Native Protein

Human Apo B-100

Apolipoprotein B-100 (Apo B-100)

Human Apolipoprotein B-100 (Apo B-100). Devoid of Apo(a), Apo C, and Apo E proteins. Cross-reacts with anti-LDL

Apolipoprotein B-100; Apolipoprotein B-100; apolipoprotein B-100; apoB-48; apoB-100; apo B-100; mutant Apo B 100; OTTHUMP00000115994; apolipoprotein B48; apolipoprotein B (including Ag(x) antigen)

APOB; APOB; FLDB; LDLCQ4

APOB_HUMAN

Human Plasma LDL

4563

Apolipoprotein B-100 (Apo B-100)

Method of purification:. 1. Ultracentrifugation at d 1.03-1.05 . 2. Delipidation with diethyl ether:ethanol (3:1). 3. Gel filtration over Sephacryl S-200

Purified, Liquid

2.1 mg/ml (BCA method)

Store at 2 to 8 degree C. DO NOT FREEZE.

Specific methodologies have not been tested using this product.

Note: Centrifuge before opening to ensure complete recovery of vial contents

Buffer: 200cmM Tris, 2 mM Sodium Decyl sulfate, pH 8.25. Preservative: None. Warnings: All human source materials have tested negative for HIV 1, HIV 2 and HCV antibodies, and HBsAg. No test guarantees a product to be non-infectious. Therefore, all material derived from human fluids or tissues should be considered as potentially infectious.

Purified Lipoproteins

Human Apo B-100. Human Apolipoprotein B-100 (Apo B-100). Deviod of Apo (a), Apo C, and Apo E proteins. Cross-reacts with anti-LDL.

114014

P04114.1

P04114

Cell Surface Interactions At The Vascular Wall Pathway (106062); Chylomicron-mediated Lipid Transport Pathway (106157); FOXA1 Transcription Factor Network Pathway (137979); Fat Digestion And Absorption Pathway (194385); Fat Digestion And Absorption Pathway (194324); Formation Of Platelet Plug Pathway (106029); Hemostasis Pathway (106028); LDL-mediated Lipid Transport Pathway (106159); Lipid Digestion, Mobilization, And Transport Pathway (106111); Lipoprotein Metabolism Pathway (106156)

This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA- UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq]

Function: Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Subcellular location: Secreted. Induction: Up-regulated in response to enterovirus 71 (EV71) infection (at protein level). Ref.34. Post-translational modification: Palmitoylated; structural requirement for proper assembly of the hydrophobic core of the lipoprotein particle. Ref.31. Involvement in disease: Defects in APOB are a cause of hypobetalipoproteinemia familial type 1 (FHBL1) [. MIM:107730]. A disorder characterized by highly reduced plasma concentrations of low density lipoproteins, and dietary fat malabsorption. Clinical presentation may vary from no symptoms to severe gastrointestinal and neurological dysfunction similar to abetalipoproteinemia. Ref.46Defects in APOB are a cause of familial ligand-defective apolipoprotein B-100 (FDB) [. MIM:144010]. FDB is a dominantly inherited disorder of lipoprotein metabolism leading to hypercholesterolemia and increased proneness to coronary artery disease (CAD). The plasma cholesterol levels are dramatically elevated due to impaired clearance of LDL particles by defective APOB/E receptors. Ref.40 Ref.42 Ref.44Note=Defects in APOB associated with defects in other genes (polygenic) can contribute to hypocholesterolemia. Sequence similarities: Contains 1 vitellogenin domain. RNA editing: Edited at position 2180.The stop codon (UAA) at position 2180 is created by RNA editing. Apo B-48, derived from the fully edited RNA, is produced only in the intestine and is found in chylomicrons. Apo B-48 is a shortened form of apo B-100 which lacks the LDL-receptor region. The unedited version (apo B-100) is produced by the liver and is found in the VLDL and LDL. Sequence caution: The sequence AAA51752.1 differs from that shown. Reason: Frameshift at positions 942, 951, 1139, 1165, 1164, 1371 and 1385.

1 mg

255 USD